168 related articles for article (PubMed ID: 31235543)
1. Feasibility of combined screening for upper gastrointestinal adenocarcinoma risk by serology and Cytosponge testing: the SUGAR study.
Xu Y; Miremadi A; Link A; Malfertheiner P; Fitzgerald RC; Bornschein J
J Clin Pathol; 2019 Dec; 72(12):825-829. PubMed ID: 31235543
[TBL] [Abstract][Full Text] [Related]
2. Cytosponge-trefoil factor 3 versus usual care to identify Barrett's oesophagus in a primary care setting: a multicentre, pragmatic, randomised controlled trial.
Fitzgerald RC; di Pietro M; O'Donovan M; Maroni R; Muldrew B; Debiram-Beecham I; Gehrung M; Offman J; Tripathi M; Smith SG; Aigret B; Walter FM; Rubin G; ; Sasieni P
Lancet; 2020 Aug; 396(10247):333-344. PubMed ID: 32738955
[TBL] [Abstract][Full Text] [Related]
3. Use of a Cytosponge biomarker panel to prioritise endoscopic Barrett's oesophagus surveillance: a cross-sectional study followed by a real-world prospective pilot.
Pilonis ND; Killcoyne S; Tan WK; O'Donovan M; Malhotra S; Tripathi M; Miremadi A; Debiram-Beecham I; Evans T; Phillips R; Morris DL; Vickery C; Harrison J; di Pietro M; Ortiz-Fernandez-Sordo J; Haidry R; Kerridge A; Sasieni PD; Fitzgerald RC
Lancet Oncol; 2022 Feb; 23(2):270-278. PubMed ID: 35030332
[TBL] [Abstract][Full Text] [Related]
4. Serum trefoil factor 3 is a promising non-invasive biomarker for gastric cancer screening: a monocentric cohort study in China.
Huang Z; Zhang X; Lu H; Wu L; Wang D; Zhang Q; Ding H
BMC Gastroenterol; 2014 Apr; 14():74. PubMed ID: 24720760
[TBL] [Abstract][Full Text] [Related]
5. Prevalence of Helicobacter pylori infection in 160 patients with Barrett's oesophagus or Barrett's adenocarcinoma.
Lord RV; Frommer DJ; Inder S; Tran D; Ward RL
Aust N Z J Surg; 2000 Jan; 70(1):26-33. PubMed ID: 10696939
[TBL] [Abstract][Full Text] [Related]
6. Length of Barrett's oesophagus and cancer risk: implications from a large sample of patients with early oesophageal adenocarcinoma.
Pohl H; Pech O; Arash H; Stolte M; Manner H; May A; Kraywinkel K; Sonnenberg A; Ell C
Gut; 2016 Feb; 65(2):196-201. PubMed ID: 26113177
[TBL] [Abstract][Full Text] [Related]
7. Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.
Offman J; Muldrew B; O'Donovan M; Debiram-Beecham I; Pesola F; Kaimi I; Smith SG; Wilson A; Khan Z; Lao-Sirieix P; Aigret B; Walter FM; Rubin G; Morris S; Jackson C; Sasieni P; Fitzgerald RC;
BMC Cancer; 2018 Aug; 18(1):784. PubMed ID: 30075763
[TBL] [Abstract][Full Text] [Related]
8. Tests for serum levels of trefoil factor family proteins can improve gastric cancer screening.
Aikou S; Ohmoto Y; Gunji T; Matsuhashi N; Ohtsu H; Miura H; Kubota K; Yamagata Y; Seto Y; Nakajima A; Goldenring JR; Kaminishi M; Nomura S
Gastroenterology; 2011 Sep; 141(3):837-845.e1-7. PubMed ID: 21699780
[TBL] [Abstract][Full Text] [Related]
9. A non-endoscopic device to sample the oesophageal microbiota: a case-control study.
Elliott DRF; Walker AW; O'Donovan M; Parkhill J; Fitzgerald RC
Lancet Gastroenterol Hepatol; 2017 Jan; 2(1):32-42. PubMed ID: 28404012
[TBL] [Abstract][Full Text] [Related]
10. Increased detection rates of Barrett's oesophagus without rise in incidence of oesophageal adenocarcinoma.
Hurschler D; Borovicka J; Neuweiler J; Oehlschlegel C; Sagmeister M; Meyenberger C; Schmid U
Swiss Med Wkly; 2003 Sep; 133(37-38):507-14. PubMed ID: 14652799
[TBL] [Abstract][Full Text] [Related]
11. Serum pepsinogens and risk of gastric and oesophageal cancers in the General Population Nutrition Intervention Trial cohort.
Ren JS; Kamangar F; Qiao YL; Taylor PR; Liang H; Dawsey SM; Liu B; Fan JH; Abnet CC
Gut; 2009 May; 58(5):636-42. PubMed ID: 19136509
[TBL] [Abstract][Full Text] [Related]
12. Review article: Barrett's oesophagus and carcinoma in Japan.
Hongo M
Aliment Pharmacol Ther; 2004 Dec; 20 Suppl 8():50-4. PubMed ID: 15575874
[TBL] [Abstract][Full Text] [Related]
13. Non-endoscopic screening biomarkers for Barrett's oesophagus: from microarray analysis to the clinic.
Lao-Sirieix P; Boussioutas A; Kadri SR; O'Donovan M; Debiram I; Das M; Harihar L; Fitzgerald RC
Gut; 2009 Nov; 58(11):1451-9. PubMed ID: 19651633
[TBL] [Abstract][Full Text] [Related]
14. The Munich Barrett follow up study: suspicion of Barrett's oesophagus based on either endoscopy or histology only--what is the clinical significance?
Meining A; Ott R; Becker I; Hahn S; Mühlen J; Werner M; Höfler H; Classen M; Heldwein W; Rösch T
Gut; 2004 Oct; 53(10):1402-7. PubMed ID: 15361485
[TBL] [Abstract][Full Text] [Related]
15. Serological assessment of gastric mucosal atrophy in gastric cancer.
Bornschein J; Selgrad M; Wex T; Kuester D; Malfertheiner P
BMC Gastroenterol; 2012 Jan; 12():10. PubMed ID: 22289789
[TBL] [Abstract][Full Text] [Related]
16. Risk factors for Barrett's oesophagus and oesophageal adenocarcinoma: results from the FINBAR study.
Anderson LA; Watson RG; Murphy SJ; Johnston BT; Comber H; Mc Guigan J; Reynolds JV; Murray LJ
World J Gastroenterol; 2007 Mar; 13(10):1585-94. PubMed ID: 17461453
[TBL] [Abstract][Full Text] [Related]
17. Adenocarcinoma and Barrett's oesophagus. A clinico-pathological study.
Moghissi K; Sharpe DA; Pender D
Eur J Cardiothorac Surg; 1993; 7(3):126-31. PubMed ID: 8461144
[TBL] [Abstract][Full Text] [Related]
18. Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R; O'Sullivan K; Quigley EM
Endoscopy; 2006 Feb; 38(2):162-9. PubMed ID: 16479424
[TBL] [Abstract][Full Text] [Related]
19. Barrett's oesophagus: epidemiology, diagnosis and clinical management.
Whiteman DC; Kendall BJ
Med J Aust; 2016 Oct; 205(7):317-24. PubMed ID: 27681974
[TBL] [Abstract][Full Text] [Related]
20. Barrett's oesophagus: Current controversies.
Amadi C; Gatenby P
World J Gastroenterol; 2017 Jul; 23(28):5051-5067. PubMed ID: 28811703
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
